The 36-month beta value for XTNT is at -0.19. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XTNT is 115.47M, and currently, shorts hold a 0.05% of that float. The average trading volume for XTNT on July 01, 2025 was 190.08K shares.
XTNT) stock’s latest price update
Xtant Medical Holdings Inc (AMEX: XTNT)’s stock price has plunge by 17.49relation to previous closing price of 0.63. Nevertheless, the company has seen a 25.25% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-28 that Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont., May 28, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, today announced the commercial launch of OsteoFactor Pro™, a naturally occurring cocktail of allogeneic growth factors engineered to improve bone healing and support surgical success across orthopedic and spine procedures.
XTNT’s Market Performance
Xtant Medical Holdings Inc (XTNT) has seen a 25.25% rise in stock performance for the week, with a 5.72% gain in the past month and a 51.00% surge in the past quarter. The volatility ratio for the week is 8.54%, and the volatility levels for the past 30 days are at 8.49% for XTNT. The simple moving average for the past 20 days is 14.04% for XTNT’s stock, with a 38.46% simple moving average for the past 200 days.
Analysts’ Opinion of XTNT
Many brokerage firms have already submitted their reports for XTNT stocks, with BTIG Research repeating the rating for XTNT by listing it as a “Buy.” The predicted price for XTNT in the upcoming period, according to BTIG Research is $2 based on the research report published on December 05, 2023 of the previous year 2023.
Maxim Group, on the other hand, stated in their research note that they expect to see XTNT reach a price target of $6, previously predicting the price at $10. The rating they have provided for XTNT stocks is “Buy” according to the report published on November 15th, 2018.
Maxim Group gave a rating of “Buy” to XTNT, setting the target price at $10 in the report published on February 14th of the previous year.
XTNT Trading at 22.49% from the 50-Day Moving Average
After a stumble in the market that brought XTNT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.23% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XTNT starting from ORBIMED ADVISORS LLC, who sale 73,114,592 shares at the price of $0.42 back on Apr 10 ’25. After this action, ORBIMED ADVISORS LLC now owns 0 shares of Xtant Medical Holdings Inc, valued at $30,708,129 using the latest closing price.
Stock Fundamentals for XTNT
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.58 for the gross margin
The net margin for Xtant Medical Holdings Inc stands at -0.1. The total capital return value is set at -0.11. Equity return is now at value -26.20, with -12.64 for asset returns.
Based on Xtant Medical Holdings Inc (XTNT), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is -3.31.
Currently, EBITDA for the company is -7.88 million with net debt to EBITDA at -1.64. When we switch over and look at the enterprise to sales, we see a ratio of 0.9. The receivables turnover for the company is 5.21for trailing twelve months and the total asset turnover is 1.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.34.
Conclusion
In conclusion, Xtant Medical Holdings Inc (XTNT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
